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1 Introduction 
1.1 Herpesviridae 
The Herpesviridae comprises a large family of enveloped double stranded DNA viruses, with 
a broad host spectrum ranging from mammals to birds and reptiles. More than 100 different 
species of herpesviuses have been identified, including 9 human pathogenic viruses. Common 
for all herpesviruses are the ability to persist within a host in a latent state after primary 
infection. During latency only a few viral genes are expressed, thus limiting the host’s 
opportunity to establish an immune response directed against specific viral antigens. The 
latent virus can reactivate at later time points and lead to secondary infections which 
sometimes are of a different nature than the primary infection. 
1.1.1 Subfamilies and phylogeny 
Herpesviridae is divided into three different subfamilies, the alfa-, beta- and gamma-
herpesvirinae. The three subfamilies were initially separated based on biological differences 
such as cell tropism and growth properties in cell-culture. Alfaherpesvirinae are neurotrophic 
and replicate efficiently in cell culture, whereas Betaherpesvirinae have a narrower cell 
tropism in culture and infection in-vivo may results in enlargement of the infected cells 
(cytomegalia). Gammaherpesvirinae replicate poorly in culture and are oncogenic 
lymphotropic viruses. With the advances in genetics, herpesviruses are now assigned to 
subfamilies based on genomic differences. While most of the biological differences accurately 
predict the subfamily association, some viruses have been moved into a different subfamily 
after their genome was fully sequenced. This was the case for Marek’s disease virus (MDV), 
which was initially thought to be closely related to Epstein Barr virus (EBV) (a 
gammaherpesvirus) due to its ability to infect lymphocytes in addition to its oncogenicity [1]. 
Genetic analysis however revealed that the virus had more in common with alfaherpesviruses 
[2-4]. The evolutionary divergence of the three subfamilies has been predicted to have taken 
place around 400 million years ago (Figure 1.1), which is about the same time as prehistoric 
animals first started venturing onto land [5, 6]. 
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Figure 1.1: Phylogeny of the Herpesviridae. The tree represents the relationship between all 
known human pathogenic herpesviruses (for further description see 1.1.2), in addition to 
Herpesvirus Saimiri (HVS), Equine herpesvirus type 1 and 2 (EHV) and Pseudorabies virus 
(PrV). Major branches on the tree represent the three subfamilies alfa-, beta- and gamma-
herpesvirinae. Illustration modified from Antman et al. 2000 [7]. 
 
With the recent identification of two evolutionary distinct classes of herpesviruses, one 
infecting the Pacific oyster and other bivalved hosts [8], and one infecting bonefish and 
amphibians [9-11], a new herpesvirus taxonomi has been suggested. The order now known as 
Herpesviridae would be renamed Herpesvirales, with Herpesviridae as one of three families 
in this order. Alloherpesviridae (fish and amphibians) and Malaoherpesviridae (oysters) 
would make up the other two families in the new order. While the evolutionary relationships 
of single species within the different families can be defined, the time point from which the 
three families have diverged is not yet known [12]. 
1.1.2 Human herpesviruses and their clinical implications 
There are currently identified 9 different human herpesviruses, distributed over all three 
subfamilies of the Herpesviridae. Herpes Simplex virus-1, -2 (HSV-1 and -2) and Varicella 
zoster virus (VZV) belong to alfaherpesvirinae, while human cytomegalovirus (HCMV), in 
addition to Human herpesvirus-6A, -6B and -7 (HHV-6 and -7) are classified as 
betaherpesvirinae. Epstein Barr virus (EBV) and Kaposi’s sarcoma associated herpesvirus 
(KSHV) belong to the gammaherpesvirinae. Most of the viruses have a relatively high 
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prevalence in humans, with HSV-1, VZV and EBV among the most ubiquitously distributed. 
HSV-1 is reported to have a sero-prevalence of 40 – 90 % [13-15], while VZV and EBV 
generally have ~ 90 % prevalence [16, 17]. The numbers vary depending on geographical 
location and which age groups are studied. 
 
Herpesviruses are involved in a number of different diseases in humans, with alfaherpesvirus 
infections being the most extensively studied. Herpes Simplex-1 and -2 can cause recurrent 
infections of mucous membranes, with HSV-1 generally giving oro-facial lesions and HSV-2 
giving genital lesions [18]. While such infections interfere with an individual’s quality of life, 
they are seldom life-threatening. In some cases however, Herpes Simplex virus infection can 
result in more serious illnesses, like ocular infections [19, 20] or meningitis and encephalitis 
[21]. VZV is the causative agent of the childhood disease varicella (popularly called 
chickenpox). During primary infection the patient experiences fever and vesicular rash. Later 
reactivation of the virus can lead to herpes zoster and in some cases chronic pain in the form 
of post herpetic neuralgia [22].  
 
Human cytomegalovirus (HCMV) primary infections are in most cases asymptomatic, both in 
children and adults. It may however occasionally result in symptoms resembling a mild 
infectious mononucleosis with fever, myalgia and lymphadenopathy. In contrast, congenital 
HCMV infections of neonates represent a serious threat, and are connected to severe disease 
manifestations like microcephaly, chorioretinitis, nerve deafness and hepatitis [23]. 
Congenital HCMV infections occur in 0.5 – 1 % of all live births, with the majority of these 
infections being asymptomatic at birth. Although there can be a certain degree of morbidity 
connected to asymptomatic infections, the chances of severe illnesses are higher when the 
babies are symptomatic at birth. In addition to HCMV, congenital infections from HSV and 
VZV are also relatively frequent (ranging from 1 in 3200 up to 1 in 60.000 for HSV and 5 in 
10.000 for VZV [24, 25]), with local infections of the central nervous system (CNS) and 
disseminated infections involving CSN and other organs having the highest morbidity and 
mortality [26]. 
 
Most EBV infections are though to occur during childhood, resulting in sub-clinical 
infections. However, if primary infection is delayed until adolescence there is a substantial 
risk of developing mononucleosis with the possibility prolonged malaise including 
pahryngitis and lymphodenopathy [27]. As previously indicated, EBV is an oncogenic virus, 
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and although the number of people affected by EBV associated tumors in western countries 
are quite low, the situation is very different in parts of the developing world. The virus is 
thought to be associated with Burkitt’s lymphoma, which is one of the most common cancers 
affecting young children in equatorial Africa. In addition, EBV has also been linked to 
Hodkin’s disease and nasopharyngeal carcinoma [27]. KSHV generally has a low sero-
prevalence in North America and Europe (~ 5 %) [28, 29], with southern Italy and other 
Mediterranean countries having a somewhat higher prevalence [30, 31]. In sub-Saharan 
Africa, however, KSHV can be considered common with sero-prevalence ranging from 37,5 
in Zambia [32], up to 90% in Botswana [33]. Primary infection with KSHV has so far only 
been connected to mild and unspecific symptoms of diarrhea, fatigue, rash and 
lymphadenopathy [34]. Similar to EBV, KSHV has been connected to several forms of 
tumors in man. Kaposi’s Sarcoma (KS) was first described by Moritz Kaposi in the 1870s, but 
was only connected to KSHV as late as in 1994 by Chang and colleagues [35]. In addition to 
KS, which probably has a lymphatic endothelial or blood vascular endothelial origin [36], 
KSHV is also associated with the B-cell lymphomas Primary effusion lymphoma (PEL) and 
Multicentric Castleman’s disease (MCD) [37, 38]. 
 
Although Kaposi’s Sarcoma can be found in healthy individuals, then referred to as classic 
KS, both the occurrence of KS and the sero-prevalence of KSHV is substantially higher in 
people infected with human immunodeficiency virus (HIV) [39] [40]. Acquired Immune 
Deficiency Syndrome (AIDS) related KS is one of the most common malignancies found in 
AIDS patients, and is connected to increased mortality [41]. Other herpesviruses have also 
been connected to disease manifestations in AIDS patients, with increased risk of VZV herpes 
zoster and HCMV retinitis being two such examples [42, 43]. The drastic increase of KS in 
HIV positive individuals is believed to be a result of immune suppression associated with the 
HIV infection. However, immune suppression can also be a result of other circumstances. 
With the increase in organ transplant patients, and the subsequent treatment with 
immunosuppressive drugs, diseases related to herpesvirus infections are becoming more 
frequent. HCMV has been extensively reported to cause complications in both solid organ 
transplant (SOT) and bone marrow transplant (BMT) recipients. For renal transplant 
recipients, HCMV infection has been associated with increased graft rejection and renal artery 
stenosis [44, 45]. HCMV infections as a result of BMT may lead to pneumonitis, which can 
have a mortality rate as high as 80 % if left untreated [46]. Also HSV and VZV are associated 
with common complications of organ transplantations, mainly as a result of reactivation of 
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latent virus. HSV hepatitis has been connected with both SOT and BMT, where transplant 
recipients have a poor clinical prognosis if not treated early [47, 48] The incidences of herpes 
zoster as a result of VZV reactivation in individuals receiving SOT is significantly higher than 
in the general population. However, with early onset of antiviral therapy there is a low 
likelihood of visceral dissemination [49]. 
1.1.3 Structure 
Herpesvirus infectious particles have a diameter of approximately 150 - 200 nm, and can be 
divided into four separate structural elements: core, capsid, tegument and envelop (Figure 
1.2a and 1.2b). The core consists of the viral genome, which is believed to be packaged in a 
toroid shape [18, 50]. While all herpesviral genomes are made up of double stranded DNA, 
the genome size of different species can vary from 125 kbp (VZV) up to 230 kbp (HCMV) 
[51, 52]. The genome size also reflects the protein coding potential of different species with 
VZV encoding 72 open reading frames (ORFs), while HCMV encodes approximately 200 
ORFs. In addition, the genetic organization of the genomes differs between species. While the 
HSV-1 genome consists of two covalently linked segments called Long (L) and Short (S), 
each flanked by sequences of inverted repeats, the KSHV genome is made up of only one 
segment flanked by repeats [53].  
 
a     b 
           
 
Figure 1.2: Schematic overview of the herpesvirus infectious particle. a) The virus core 
consists of the vial genome (1) packaged within the capsid (2). The tegument (3) surrounds 
the capsid, and separates it from the outer membrane (4). Imbedded in the membrane are 
glycoproteins that protrude out from the virus particle (5). b) Electron micrograph of a 
Herpes Simplex 1 particle (Electron micrograph obtained from 
http://www.ncbi.nlm.nih.gov/ICTVdb)  
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The viral capsid structure is an icosahedric protein shell made up of 162 capsomers [18]. Of 
these, 12 are pentavalent capsomers located at the vertices of the capsid, while the remaining 
150 are hexavalent capsomers [54-56]. Surrounding the capsid is a more loosely structured 
tegument layer which contains more than 15 proteins in the case of HSV-1 [57]. While the 
composition and structure of the capsid is quite conserved throughout the herpesviridae, the 
composition of the tegument has a higher degree of variation between different species. There 
are however a set of at least 7 tegument proteins which are believed to be conserved between 
the three subfamilies [12]. This claim is backed up by mass spectrometry analysis of purified 
virion particles, which has confirmed the presence of many of these proteins in several 
species of herpesvirus [58-62]. The viral envelop is a double lipid layer which surrounds and 
contains the tegument proteins. Embedded in the viral envelop are a variety of transmembrane 
glycoproteins. HSV-1 reportedly contain at least 12 different glycoproteins designated gB, 
gC, gD, gE, gG, gH, gI, gJ, gK, gL, gM and gN. Of these at least 5 are conserved between the 
three subfamilies [12]. 
 
1.1.4 Infection, replication and egress 
Herpesvirus infection initiates when one or more of the glycoproteins protruding from the 
viral envelop attach to specific surface receptors on the host cell. Different herpesvirus 
species will attach to different surface receptors, which is one important factor in determining 
the tropism of a specific virus. Cell-lines that originally are non-permissive for a specific 
herpesvirus, can be rendered permissive by expressing the right surface receptor in trans. This 
has been observed for HSV-1 where the cell-line CHO-K1 (Chisese Hamster Ovary), which 
normally does not support replication of the virus, becomes permissive when transfected with 
the cellular receptor HVEM (Herpesvirus Entry Mediator) [63]. In addition to HVEM, HSV-1 
can also attach to the cellular surface proteins nectin-1 and nectin-2 [64, 65], although nectin-
2 is probably more active for HSV-2 [66]. There is also evidence that the virus utilizes 
different receptors depending on the cell being infected [67, 68]. Other cellular receptors for 
herpesviruses include Insulin degrading receptor (IDE) for VZV [69], intergrins for HCMV 
[70, 71], complement receptor 2 (CR2) for EBV [27], and DC-SIGN, xCT and Intergrin α3β1 
for KSHV [72-74].  
 
Several theories describing possible mechanisms of how the viral capsid enters the host cell 
have been proposed. The most accepted theory suggest that the interaction between the viral 
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glycoprotein and cellular receptor brings the viral envelop into close proximity of the 
cellmembrane, resulting in a fusion between the two membranes [18]. Viral tegument proteins 
and capsid are then released into the host-cell, thus initiating the infectious cycle. However, 
there are also indications that other routes of viral entry are taking place in vivo. For both 
HSV and HCMV there are reports indicating that the viruses can be endocytosed by the host 
cell, and that this also results in a productive infection [75-77]. This proposed mechanism of 
herpesviral entry is however quite recent, so many of the detail are not yet thoroughly studied, 
including how the virus is able to exit the endocytic vesicles once inside the cell. 
 
Once released into the cytoplasm, the capsid is actively transported to the nucleus along 
microtubule, and this transport is believed to be dependent on the motorproteins dynein and 
dynactin [78, 79]. Once there, the viral genome is transported through the nuclear pore 
leaving behind the empty capsid. Studies using temperature sensitive mutants of HSV-1 have 
indicated that the large tegument protein (UL36 for HSV-1) is involved in this process [80]. 
After the viral genome enters the nucleus, transcription of the viral genes occurs in a cascade-
like manner where the immediate early (IE) genes are expressed first, followed by the early 
(E) genes and finally the late (L) genes. While the IE genes mostly encode transcriptional 
activators necessary for proper expression of E and L genes, E genes encode genes involved 
in the replication of the viral genome. Late genes are first expressed after replication of the 
viral genome is initiated, and encodes to a large degree structural proteins required for making 
the viral particles [18]. 
  
Production of new virus particles is initiated within the nucleus of the infected cell, in specific 
replication compartments [81, 82]. These compartments are though to contain the structural 
proteins which make up the capsid, the proteins necessary for replicating the viral DNA, in 
addition to other proteins necessary for proper production of new viral particles. One of these 
proteins is the viral scaffolding proteins (UL26 for HSV-1), which forms a scaffold for the 
capsid proteins to assemble around [26]. The capsid structure is made up of four separate 
proteins thought to be conserved throughout the herpesviridae. Herpesviral DNA is replicated 
in a rolling circle mechanism, resulting in a long concatomeric DNA molecule where several 
viral genomes are organized in a head-to-tail fashion. The concatomoeric DNA molecule is 
subsequently cleaved into single genome fragments during the packaging process [26]. 
Packaging of newly replicated viral DNA is first initiated after the capsid-scaffold structure is 
constructed. It is believed that once DNA start entering the scaffold, the pH within the pre-
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capsid is lowered resulting in a self-cleaving of UL26 which then diffuses out through pores 
in the capsid structure [26]. For HSV, six viral proteins has been reported to be essential for 
proper packaging of the viral genome, including UL6, UL15, UL17, UL28, UL32, UL33 [83-
88]. These proteins have been designated as packaging proteins since deletions or mutation of 
any of these genes may result in partial or no packaging of the viral DNA. The two proteins 
UL15 and UL28 make up the terminase complex, and have been reported to be involved in 
cleavage of the concatomeric DNA as it is package into the capsid [89]. It is also been 
suggested that UL33 is a part of the terminase complex, and that it interacts with UL28 and 
stabilizes the UL15/UL28 complex [90, 91]. 
 
After packaging of the viral DNA, the finished capsid is believed to acquire an initial 
tegument layer within the nucleus. The composition of this initial tegument is however not 
known. The capsid is subsequently transported through the inner nuclear membrane and into 
the perinuclear space, obtaining an initial viral envelop in the process. Two viral proteins, 
UL31 and UL34 in HSV-1 (labeled the nuclear egress complex (NEC)), has been reported to 
play an important role in the nuclear egress of herpesviruses [92]. Orthologs of these proteins 
has also been reported to share similar function in Pseudorabies virus (PrV) [93], mCMV [94] 
and EBV [95]. It is believed that the initial viral envelop is lost when the viral particle fuses 
with the outer nuclear envelop, releasing the uncoated virus into the cytoplasm. For HSV, the 
viral kinase US3 is reported to play an important role in this process, due to the observation 
that US3 deletion mutants accumulate in the perinuclear space [96]. Once released into the 
cytosol, the viral particle acquire its final tegument, and goes through a second envelopment 
when it is transported into the trans-golgi [97, 98]. The details of how the viral particle is 
transported into the golgi is not fully known, but for PrV and EHV-1 (Equine herpesvirus 1) 
the conserved proteins gM and UL11 has been reported to play an important role [99-101]. 
Final egress out of the infected cell goes through sectretorial vesicles budding off from the 
golgi. 
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Figure 1.3: Overview of the infectious cycle of herpesviruses. The viral particle attaches to 
receptors on the cell surface which leads to a fusion between the viral envelop and the 
cellular membrane. Once released inside the cell the capsid is transported along the 
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microtubule to the nuclear membrane, where the viral genome is transported into the nucleus 
through the nuclear pore. The viral genes are expressed in a cascade-like fashion with IE 
genes generally being transcriptional regulators controlling the expression of the E and L 
gene classes. After replication of the viral genome is initiated, the structural proteins 
necessary for generating new infection particles is expressed. Newly replicated DNA is 
packaged into preformed capsids which are subsequently transported from the nucleus to the 
perinuclear space through the inner nuclear membrane. During this process the virus gains 
an initial viral envelope which is subsequently lost when the virus particle buds through the 
outer nuclear membrane. In the cytoplasm the virus particle recruits its final tegument, and 
receives is final envelop when transported into the trans-golgi network. The viral particle is 
transported out of the cell through secretarial vesicles. 
 
1.1.5 Latency 
 
All herpesviruses are able to enter a latent stage of infection where only a few genes are 
expressed. By limiting the number of proteins expressed the virus can minimize the viral 
epitopes presented by class I MHC, and thus prevent detection by cytotoxic T-lymphocytes 
(CTL). Latently EBV infected B-cells from healthy individuals generally express only two 
viral proteins, LMP2A (Latent Membrane Protein) and EBNA1 (EBV Nuclear Antigen) [102, 
103]. Even though the proteins are expressed, they do not simulate any significant CTLs 
response. EBNA1 manages this through a domain of glycine-alanine rich repeats (GAr) which 
inhibits its proteasomal degradation, and subsequent peptide presentation. The exact 
mechanism of how EBNA1 escapes the proteasome is not fully elucidated, but it has been 
suggested that the GAr binds to the 19S cap of the 26S proteasome and prevents further 
processing of ubiquiniated substrates [104]. LMP2A also shows resistance to epitope 
presentation through the proteasome pathway which can be related to specific amino acids in 
its C-terminal domain [105]. This resistance can however be abrogated in vitro if cells are 
exposed to INF-γ [106]. A similar situation can be seen for HCMV, where the most 
immunodominant CTL epitopes are directed against a few proteins expressed during the lytic 
cycle [107, 108].   
 
During latency the viral genome is attached to the host chromosomes, and is replicated with 
the host chromosomes during mitotic cell-division [26, 53]. For KSHV it has been reported 
that LANA1 (Latency Associated Nuclear Antigen 1) is responsible for tethering the viral 
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genome to the cellular chromosomes through binding to histones H2A-H2B [109]. EBNA1 
has a similar function to LANA1 in EBV, and is reported to attach to host chromosomes 
through its N-terminal domain [110]. While there are reports indicating that EBNA1-mediated 
persistence of the viral genome is dependent on interactions with EBP2 (the chromosome 
associated protein EBNA Binding Protein 2) [111, 112], this has been disputed by others 
[110].  
 
As previously mentioned, there are only a few viral genes expressed during latency, with the 
majority of genes only being expressed when the virus enters the lytic replication cycle. This 
is reflected in the epigenetic regulation of lytic genes which, during latency, have a condensed 
chromatin structure (heterochromatin), in accordance with transcriptional silencing [113, 
114]. One of the hallmarks of heterochromatin formation is methylation of lysine 9 on histone 
3 (H3K9me), and recruitment of heterochromatin binding proteins 1 (HP1) [115, 116]. 
Acetylation of H3, on the other hand, is located at sites of transcriptional activation and a 
more open chromatin structure [117]. Ioudinkova and colleagues have shown that HCMV 
lytic genes, like the viral polymerase (UL54), pp65 (phosphoprotein/UL83) and pp150 
(phosphoprotein/UL32), are indeed methylated on H3 during latency, and acetylated on H3 
when expressed in the lytic cycle [118]. Similar results have been shown for HSV, where the 
LAT (Latency associated transcript) has been reported to be important for heterochromatin 
formation on lytic genes during latency [119]. For KSHV, it has been shown that 
demethylation of the ORF 50 promotor, ORF 50 being the lytic transactivator RTA, is enough 
to change the infection from a latent to lytic state [120].   
 
More recently it has been reported that some herpesvirus species also express micro-RNAs 
(miRNAs) during latency [121, 122]. miRNA are short (~22 nucleotide) RNA transcripts 
involved in gene regulation, that can bind to specific mRNAs and inhibits its further 
translation. HSV-1 encodes a miRNA within its LAT-transcript, and KSHV encode at least 12 
miRNA within its K12 region [121-124]. Although the target mRNAs for most of these 
miRNA are still missing, HSV-1 LAT miRNA has been reported to inhibit apoptosis of 
infected cells through down-regulation of TGF-β1 (transforming growth factor, 1 beta) and 
SMAD3  [122]. A recent study from KSHV has also suggested several targets for the 12 
miRNAs, including the tumor suppressor gene thromospondin 1 (THBS1) [125].  
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1.1.6 Conserved and non-conserved genes 
Herpesviruses encode a set of orthologous genes, or core genes, which can be found in 
members of all three subfamilies. The published number of conserved genes varies from ~ 26 
to ~ 40  depending on the stringency of the methods used by the authors [12, 126-128]. When 
only taking sequence similarity into consideration the number of conserved genes is limited to 
around 30. However, several proteins are believed to share similar function although they 
show a very low sequence similarity. This is especially true for some of the structural proteins 
that make up the capsid. When these proteins are included the number of core proteins rises to 
approximately 40. The herpesviral core protein are generally cluster in the center of the viral 
genome (Figure 1.4), and are involved in the fundamental aspects of viral replication (e.g. 
DNA replication, DNA packaging, structure and egress). This is reflected in that a large 
portion of the core genes are essential for the virus to replicate in cell culture [129-131]. 
Genes involved in immune escape generally encode non-core proteins, which often are non-
essential for growth in cell culture. They can however be required for the virus to properly 
infect and replicate in a host organism. 
 
While core proteins are derived from an ancestral herpesvirus, before the separation into three 
distinct subfamilies, the remaining proteins encoded in the viral genome are divided into 
subfamily and species-specific genes most likely acquired more recently. About 13 % of the 
herpesviral genes have been found to have sequence similarity to human genes [132]. The 
majority of these proteins are species or sub-family specific, with the exception of four core 
poteins (including ribonucleotide reductase large subunit (HSV-1 UL39), uracil-DNA 
glycosylase (HSV-1 UL2), helicase/primase (HSV-1 UL5) and DNA polymerase (HSV-1 
UL30)). 
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Figure. 1.4 Genomic organization of conserved genes in herpesviruses, represented by HSV-
1, KSHV and HCMV. Protein coding regions corresponding to core genes are shown in blue 
color, while non-conserved genes are colored yellow. The core genes are divided into seven 
conserved geneblocks labeled I-VII, which are differentially organized in the different 
subfamilies. Introns are in white color, and the ATPase subunit of the terminase complex, the 
only gene also conserved between Herpesviridae, Alloherpesviridae and Malaoherpesviridae, 
is indicated in red. Modified from [133] 
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1.2 System biology 
 
1.2.1 Definition of system biology 
Systems biology is the study of the interactions between the components of a biological 
system, and how these interactions give rise to the function and behavior of that system 
(definition taken from Wikipedia (http://www.wikipedia.org)). While the ultimate goal of 
systems biology is to give a complete and accurate model of how all the different components 
of a cell behave and interact with each other, current studies are generally limited to 
examining one type of component (e.g. protein or RNA) or one defined type of interaction 
(e.g. protein-protein or enzyme-substrate) at a time. This has spawned several sub-disciplines 
that all fall within the category of systems biology: interactomics which focuses on protein-
protein or protein-DNA interactions [134], proteomics which focuses on identifying and 
quantifying proteins (mainly through mass spectrometry) [135], transcriptomics which look at 
expression of RNA and how this is influenced by internal and external factors [136], and 
metabolomics which detects and measures levels of different metabolites [137]. Common for 
all these fields is that studies often produce large quantities of data which require further 
processing using different bioinformatics tools. Advances in bioinformatics has also resulted 
in the possibility of combining data obtained from different sub-disciplines, resulting in a 
more complete picture of what goes on in a cell or an organism [138]. 
 
1.2.2 Yeast-two-hybrid 
Yeast-two-hybrid (Y2H) as a method for looking at protein-protein interactions was first 
described in 1989 by Fields and Song [139]. They divided the transcription factor GAL4 
(DNA-binding transcription factor required for the activation of the GAL genes in response to 
galactose; repressed by Gal80p and activated by Gal3p) into two separate domains, its DNA 
binding domain (DB) and transcription activating domain (AD), and then fused different 
proteins to these domains. If protein A fused to DB interacts with protein B fused with AD the 
complete transcription factor is reconstituted allowing the transcription of a reporter gene. 
Theoretically any reporter gene can be used to visualize an interaction between proteins A and 
B, but the HIS3-gene reporter system is one of the most widely used. By placing the HIS3 
gene, encoding imidazoleglycerol-phosphate dehydratase which is essential for yeast to 
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synthesize histidine, it is possible to identify interacting proteins based on the yeast clones 
ability to grow in media lacking histidine [140].  
 
 
 
Figure 1.5 Principle of Yeast-two-hybrid. A protein of interest is fused to the DNA binding 
domain of the GAL4 transcription factor (referred to as the bait protein), while a second 
protein is fused to the activator domain of GAL4 (referred to as prey protein). If the prey and 
bait protein interact they reconstitute the GAL4 transcription factor which induces the 
transcription of a reported gene. (Modified from the Matchmaker GAL4 Two-Hybrid System 3 
& Libraries User Manual (Clontech)) 
 
Two different approaches can be used when identifying protein-protein interactions by yeast-
two-hybrid, the matrix screen and the library screen. The matrix screen approach requires that 
you have a fixed set of known proteins to be tested against each other for the ability to 
interact, and that you have all the proteins as fusion constructs with either the AD (prey) or 
the BD (bait) domain (or preferentially both). For a set of 10 proteins, protein 1 as prey can 
then be tested individually against proteins 2-10 as baits. Since the identity of all the proteins 
tested are known, it is possible to immediately identify the interacting proteins. In a library 
screen approach a single protein as bait is analyzed against a library of prey proteins. Since 
the identity of the interacting prey is not known in a library screen, all positive interactions 
have to be sequenced to identify the prey proteins. Generally, a matrix screen is faster and 
cheaper since positive samples do not have to be sequenced. However, the need to clone each 
protein to be tested in a matrix screen separately makes it less convenient to use in genome-
wide studies. While a library screen allows you to screen for more possible interactions, the 
quality of the analysis is heavily dependent on the quality of the prey libraries.  
 
While currently the most commonly used method for large-scale analysis of PPIs, Y2H 
screens are troubled by the presence of false negative and false positive interaction. False 
negative interactions are PPI that occur in the cell, but fail to be detected by the Y2H analysis, 
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and affect the coverage of the analysis. In contrast, false positive interactions are not observed 
in the cell, but are still found to be positive in the Y2H analysis, resulting in lower specificity. 
The false positive rate in Y2H have been reported to be around 50 %, and remains a serious 
problem in generating reliable data using this technique [141, 142]. This problem can 
however be addressed by retesting interactions using a second independent analysis, with 
variants of co-immunoprecipitation being among the most commonly used techniques. False 
negative interactions are however more difficult to assess, since one would need a complete 
set of verified interactions to know how many are being missed. It is however apparent from 
comparative studies that there is generally little overlap between large-scale Y2H studies, 
indicating a high degree of false negative interactions [143-145]. 
1.2.3 Large-scale interactome studies 
The first two organisms analyzed, on a genome-wide level, for protein-protein interactions 
were the bacteriophage T7 virus and Vaccinia virus [146, 147]. Both of which have relatively 
small genomes encoding few proteins. However, recent advances made to the Y2H technique, 
as well as the introduction of robotics, have made it possible to screen large number of 
proteins against each other. This resulted in the first large-scale interactions network (also 
referred to as an interactome) for Saccharomyces cerevisiae being published by Uetz et al in 
2000 [148]. In addition to the publication of a more comprehensive study of interactions in 
yeast [149], large scale interaction maps have also been generated for Helicobacter pylori 
[150], Caenohabditis elegans [151], Drosophila melanogaster [152], Plasmodium falciparum 
[153] and Homo sapiens [154, 155].  
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Figure 1.6: Map of protein-protein interactions in Saccharomyces cerevisiae. Circles 
represent proteins (nodes), and the lines between them (edges) indicate an observed 
interaction. The colors refer to the phenotypic effect observed when deleting a specific 
protein. Removal of a red node is lethal for the yeast, green are non-lethal, orange result in 
slower growth and yellow are unknown. Modified from [156]. 
 
While the previously mentioned interactomes are all derived from Y2H experiments, there are 
also other means of generating large interaction networks. Two genome-wide tandem affinity 
purification (TAP) studies, where protein complexes were purified from yeast and identified 
by mass spectrometry (MS), were recently published [157, 158]. The benefit of pulldown 
experiments is the ability to detect both direct interactions in addition to indirect interaction 
(where two proteins are part of the same complex, but do not interact directly with each 
other). By identifying which complexes a particular protein is part of, one can get a better 
picture of which cellular processes the protein is involved in. Another possibility is to 
generate interaction networks by predicting PPIs in one organism based on experimentally 
observed interaction from a model organism. This method have been used to generate 
predicted human interaction networks, where S. cerviciae, D. melanogaster and C. elegans 
were used as model organisms [159]. Finally, it is also possible to generate networks based on 
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expression data [160]. By correlating how different genes are expressed during cell-cycle 
progression, or when stimulated with a specific substance, genes that show similar expression 
patters are indicated as having interactions between them. These transcription networks can 
give a good indication of genes which are involved in similar processes, which can then be 
further analyzed for direct interactions. The accuracy of expression correlation networks or 
other predicted networks can be increased by also including additional information, such as 
gene annotation and gene domain information [161]. 
 
The ever increasing amount of published protein-protein interactions have made it possible to 
text-mine the current literature, either manually or by using bioinformatic tools, to generate 
large interaction networks based on the results [162]. Individual interactions in these networks 
often have the benefit of being more thoroughly investigated, possibly resulting in a lower 
level of false positive interaction. These networks can however be somewhat biased towards 
proteins that have been more extensively studied, and does not necessary give a complete 
picture of interactions in a given organism. 
 
1.2.4 Network topology 
One common feature of cellular PPI networks is that a small portion of proteins have many 
interaction partners (so called hubs), while most proteins are only involved in a few 
interactions (Figure 1.6). What separates a PPI network from random distribution networks is 
the presence of these highly connected hubs, which tie together most of the proteins with only 
one or two interaction partners (Figure 1.7). The result is a very dense network where the 
distance between any two proteins (the number of edges one has to follow to get from one 
protein to another) is generally quite low. For the yeast network published by Schwikowski 
and colleagues, the average distance between any two proteins is only 3.05 [163]. Due to the 
generally small distance between any two proteins in these network, they are referred a being 
small-world networks. This phenomenon is not exclusive for cellular PPI networks, but was 
indeed initially observed in a study of the structure of the World Wide Web [164]. Later 
studies has determined that other networks, such as citation networks, food webs, metabolic 
networks and proteins-protein interaction networks share the same general network topology 
[155, 165, 166]. 
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Figure 1.7: Random vs scale-free degree distribution. For a randomly connected graph, the 
number of links for each protein p(k) follow a Poisson distribution where p(k)~e-k. This graph 
has a clear peak (k), indicating the most common degree among its nodes. Scale-free 
networks however, do not have a clear peak in the distribution. While most nodes only have a 
few links, a few nodes have a large number of links (indicated in grey). The degree 
distribution of a scale-free network follow a power-law distribution where p(k)~k-γ. Modified 
from [165, 167]  
 
These networks follow a scale-free topology, characterized by a degree distribution which 
follows a power-law relationship: 
 
P(k) describes the number of proteins in the network which has a given degree (number of 
interactions), while γ indicates a coefficient which describes the decline of the graph (γ will 
vary between different networks) (Figure 1.7) [156]. The first cellular networks to be 
classified as having a scale-free topology was S. cerevisiae and Helicobacter pylori [156], and 
this topology has later been confirmed for most other cellular networks studied. 
 
Cellular networks also tend to display modularity, with certain highly interconnected proteins 
forming sub-modules within the interaction network. These modules often correlate to 
specific complexes or groups of proteins with similar functions that have many interactions 
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between them. The subunits of the proteasome are one example of proteins that are highly 
interconnected which may stand out as a sub-module in the cellular network [168]. 
 
1.2.5 Extracting biological information from interactomes  
 
With the increasing number of large-scale interactomes being published, there is a growing 
interest in analyzing these networks by different bioinformatical means. A large number of 
studies have described the topological properties of these networks in more detail. Although, 
it is yet unclear why cellular networks display a scale-free topology, one can speculate that it 
has some biological relevance for the cell. One possible explanation lies in the fact that scale-
free networks have a relatively high tolerance against random failures (i.e. if one random 
protein should be taken out of the network) [169]. In vivo this could correlate to a given 
mutation rendering a protein unable to fulfill its original function, or being knocked down 
through siRNA interference. From studies in yeast it has been observed that the loss of a 
single gene will in most cases not be lethal to the organism [170, 171]. However, there are 
some proteins that are essential to the cell, where removal of one protein can have a profound 
effect on the cell. One of the hallmarks of scale-free networks is that, while tolerant to random 
failure, they are highly susceptible to targeted attacks. When the hubs of a scale-free network 
are removed one-by-one the overall network quickly collapses [169]. Similar finding have 
been reported for cellular network. In example, studies done in yeast have shown that there is 
a correlation between centrality (number of interactions) and lethality in the yeast PPI 
network, indicating that hubs have a higher probability of being essential [156, 172]. This 
finding has however been disputed in a separate study [173]. In addition, hubs have been 
suggested to have a higher probability of being involved in cancer development [174], and 
two separate studies has indicated that hubs tend to be more conserved than proteins with few 
interaction partners [175, 176].With hubs seemingly having such a central role in both 
interaction networks, and in the biology of the organisms, there is now an increased effort to 
discover what separates these proteins from other proteins. Several suggestion have already 
been proposed, such as hubs have higher intrinsic disorder (domain which are more loosely 
folded) [177-179], more sequence repeats [177] and higher portion charged residues on the 
protein surface domains [179]. Whether these are the only factors involved is more doubtful, 
and further studies will most likely reveal other, and possibly more important, differences 
between hubs and non-hubs. 
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As more interactomes are becoming available, the possibility of comparing these networks 
against each other has become more apparent. This has spawned the field of comparative 
interactomics which seeks to explore the similarities and differences of biological networks. 
This approach has been used to identify conserved interactions between different species 
[173, 180], and new bioinformatical tools now has the possibility to align different networks 
similar to what is generally done for amino acid or nucleotide sequences [181]. 
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2 Aims of the study 
Throughout the replication cycle of herpesviruses there are a multitude of protein-protein 
interactions taking place which ensures the production of new infectious viral particles. 
Gaining a better understanding of how the viral proteins interact with each other and with 
cellular proteins will help elucidate the details of the viral replication cycle, and possibly aid 
in the identification of new drug targets. The aims of this study will further be described in 
three paragraphs: 
 
I Intra-viral interactions 
Herpesviral proteins interact with each other at different stages during the infection (e.g. 
replication of viral DNA, capsid formation and viral egress). We aim to study intraviral 
protein-protein interactions in several species of herpesvirus on a genome-wide level using 
the yeast-two-hybrid system. To achieve this we will clone the complete ORFeomes of the 
five herpesviral species HSV-1, VZV, mCMV, EBV and KSHV, and analyze the proteins for 
the ability to interact with each other. Resulting interaction networks will be further processed 
using bioinformatical tools, and potentially interesting interaction will be studied in more 
detail. 
 
II Virus-host interactions 
Protein-protein interaction between viral and cellular protein will be studied for VZV and 
KSHV to better understand how herpesviruses are able to take control over a host cell. The 
two virus-host networks will be compared to identify common cellular targets for the two 
viruses, and to elucidate on general strategies which herpesviruses apply to gain control over 
a host cell. 
 
III Conserved interactions  
Using the large datasets of intraviral PPIs obtained, we wish to identify interactions that are 
conserved between closely and remotely related herpesvirus species (e.g within a subfamily 
and between subfamilies). Using bioinformatics tools we hope to identify specific factors 
which may help determine if interactions are conserved or not. 
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4 Summary of papers 
 
4.1 Paper I 
 
Herpesviral Protein Networks and Their Interactions with the Human Proteome 
The first paper presents the genome-wide yeast-two-hybrid (Y2H) analysis of intraviral 
protein-protein interactions (PPI) in the two herpesviruses Kaposi’s sarcoma associated 
herpesvirus (KSHV) and varicalla zoster virus (VZV). A total of 89 KSHV ORFs were cloned 
and analyzed for PPIs, revealing 123 interactions between 50 ORFs. For VZV, 69 ORFs were 
analyzed and 173 interactions observed between 59 ORFs. Approximately 50 % of the 
interactions detected in the Y2H screen for KSHV could be confirmed in an independent co-
immunoprecipitation (CoIP) assay. While the viral network shared some characteristics with 
cellular networks, like having relatively many hubs (typical for a scale-free networks), they 
differed in other parameters. The most common number of interactions for the KSHV proteins 
was three, which is in contrast to cellular networks where one single interaction is the most 
common. Therefore, the herpesviral networks appear as highly connected modules, and 
display a power-law distribution that is divergent from known scale-free networks. Due to a 
lack of known virus-host interactions, the viral networks could not be integrated into a 
cellular network based on published interactions alone. In order to circumvent this problem, 
virus-host interactions were predicted based on homology to known interactions in S. 
cerevisiae, C. elegans and D. melanogaster. Altogether 20 virus-host interactions were 
predicted using this method, allowing the viral networks to be successfully connected into the 
human interaction network. From 19 of the predicted interactions, 13 could be confirmed by 
CoIP. As the predicted virus-host interactions were added to the viral network, the combined 
virus-host networks adapted to a scale-free topology which was more similar to other known 
cellular interaction networks. These findings suggest that while viral interaction networks 
differ from cellular networks when considered separately, they adapt a topology more similar 
to cellular networks once connected into a host network. 
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4.2 Paper II 
 
Herpesviral proteins preferentially target highly connected human host proteins 
This paper presents two Y2H screens identifying protein-protein interactions between viral 
and cellular proteins. For KSHV, the complete ORFeome (from Paper I) was analyzed against 
a cellular clone collection initially presented by Stelzl and colleagues [155]. From more than a 
million KSHV-host interactions analyzed in an all-against-all matrix approach, 252 
interactions between 49 viral and 131 cellular proteins were observed. For VZV, a library 
Y2H analysis was performed, revealing 876 interactions between 61 viral and 755 cellular 
proteins. If more stringent criteria were used, a high confidence (HiFi) dataset of 154 
interactions between 38 VZV and 145 cellular proteins were obtained. From the KSHV-host 
network, a subset of interactions was analyzed by co-immuno precipitation, and 
approximately 50% of the interactions could be confirmed. Although there was little overlap 
between the two virus-host networks, a set of 13 cellular proteins were targeted by both 
viruses, and two of these proteins were targeted by orthologous proteins in VZV and KSHV. 
While 12 of 13 common targets were never before reported to interact with any herpesvirus 
protein (RPA1 interacts with EBNA1 [182]), several of the proteins could be connected with 
different aspects of herpesvirus morphogenesis. 
 
Bioinformatical analysis of the two virus-host networks indicated that the viral proteins 
preferentially interacted with highly connected cellular proteins (hubs). This tendency was 
observed for both VZV and KSHV, indicating that the targeting of hubs might be a common 
feature for herpesviruses. When comparing the number of virus-host interactions to the 
number of intraviral interactions (from Paper I) for each viral protein, it was observed that 
different viral proteins acted as hubs in the two networks. (i.e. proteins with many intraviral 
interactions generally had quite few virus-host interactions). Further, if the viral proteins were 
sub-divided into conserved (core) proteins and non-conserved (non-core) proteins, core 
proteins were more likely to interact with highly connected cellular proteins than non-core 
proteins. In addition, the core proteins were observed to have significantly more cellular 
interaction partners than the non-core proteins. Taken together, these finding present a well of 
new virus-host interactions for two species of herpesvirus, and an insight into the strategies 
herpesviruses use to gain control over a host cell. 
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4.3 Paper III 
 
Comparative interactomics point to evolutionary conserved herpesviral protein-protein 
interaction networks.  
This paper presents the genome-wide analysis of protein-protein interactions in HSV-1, 
mCMV and EBV. Altogether 941 intraviral PPIs were observed, including 113 interactions in 
HSV-1, 397 in mCMV and 190 in EBV. When these data were combined with the two 
networks presented in the first paper, a dataset of 1007 interaction in five different 
herpesvirus species were obtained. From 492 interactions between viral proteins conserved in 
more than one species, 137 were actually observed in two species or more. Although there 
were a significant number of conserved interactions between all the five species, only two 
interactions were observed in four species (and none in all five). 
 
Herpesviruses encode 41 core proteins which are present throughout the three subfamilies. Of 
the 218 non-redundant interactions observed among these core proteins, 47 were detected in 
more than one species. There was however no correlation between the sequence similarity of 
a gene, and the number of species in which an interaction were confirmed. To evaluate if 
interaction among core proteins were conserved or species specific we predicted interactions 
in HSV-1, mCMV and EBV based on the interaction network of KSHV. A total of 92 
predicted interactions were analyzed by CoIP, of which ~ 60% could be confirmed, indicating 
that many interactions among core protein are conserved. There was also a significant 
correlation between the number of interactions confirmed by CoIP, and the number of 
herpesviruses in which an Y2H interaction was observed. This suggests that the interactions 
observed in several species may be considered of higher confidence than interactions only 
observed in one species. 
 
An interesting interaction between the mCMV proteins M51 and M53 was further evaluated 
by immuno-fluorescence using fluorescent fusion proteins. M51 was observed to co localize 
with both M53 and M50 in transiently transfected HeLa cells, possibly reflecting a functional 
connection between these proteins.  
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5 Discussion 
 
5.1 General results and methodology 
The three papers presented here describe an extensive study of viral-viral and viral-host 
protein-protein interactions (PPI) using yeast-two-hybrid (Y2H) as the main experimental 
method. From the intraviral interaction networks of five different herpesvirus species it was 
observed that these networks differ topologically from cellular networks. However, when two 
of the viral networks were connected to a cellular network, through predicted interactions, the 
combined networks adopted a topology similar to previously published cellular networks. 
Although there was little overlap between the five viral networks, an unrooted phylogenetic 
three (based on the neighbor joining algorithm) could still be obtained using PPI as the only 
data source. Further, the generation of a core network, where interactions among core 
herpesviral proteins from all five viruses were overlaid, allowed the extraction of interesting 
interactions which were not apparent in each single network. Two separate genome-wide 
studies of virus-host PPI for KSHV and VZV indicate that there are common cellular targets 
between the two viruses, and suggests that herpesviral proteins preferentially interact with 
highly connected cellular proteins (hubs).  
 
All three studies presented here rely heavily on Y2H as a method for detecting protein-protein 
interactions. As indicated in the introduction, this method is error-prone with relatively high 
numbers of false positive and false negative interactions. There are however means for 
addressing these problems in order to obtain more reliable data. Some proteins, mostly bait-
proteins, are known to be able to promote the transcription of the reporter gene without the 
presence of an interacting prey-protein. These proteins are referred to as self-activators, and 
can be a major source of false positive interactions. Using a chemical inhibitor (3-amino-1, 2, 
4-triazole (3-AT) (Invitrogen)), which inhibits histidine biosynthesis [183], it is possible 
lower the self-activation of these proteins [184]. In the studies presented here, all viral bait 
proteins were tested for self-activation, and self-activating baits were further analyzed on 
rising concentrations of 3-AT. The proteins which displayed self-activation on high 
concentrations of 3-AT, were taken out of the results. Another commonly used method for 
increasing the specificity of the Y2H results is to test interactions more than once. This can 
either be done by retesting observed interactions, or testing each interaction in 
duplicates/quadruplicates. For the five intraviral networks, all interactions were tested in 
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quadruplicates, with the exception of mCMV which was tested in duplicates. The KSHV-host 
interaction analysis was based on a matrix Y2H approach, and all interactions observed in the 
initial analysis were retested, and only interactions confirmed in the retesting were included in 
the results. For the VZV-host analysis, a library Y2H approach was undertaken, and all 
observed interactions were included in the VZV-all dataset, including interactions only 
observed once. However, interactions observed more than once were considered to be of 
higher confidence, and make up the VZV-HiFi dataset (Paper II). Since all the interactions 
presented in these three studies, with the exception of the VZV-all dataset, have been 
observed at least twice, we believe that the false positives rate have been brought down to a 
reasonable level. From the KSHV intraviral, and KSHV virus-host studies, approximately 
50% of the observed interactions could be reproduced using CoIPs as a second method, which 
is in accordance with similar publications [155, 185]. Since our CoIP system is based on over-
expressing tagged proteins using Vaccinia virus, it is possible that this system also is 
burdened with false positive and false negative interactions. However, in Paper III 
(Supplemental Figure 10) we observed a good correlation between conserved core 
interactions detected by Y2H, and core interactions confirmed by CoIP. From this finding we 
conclude that the two methods support each other, and that interactions observed by both 
Y2H and CoIP most likely are true positives. 
 
Determining the false negative rate is however more difficult. Paper III indicate that there is 
in general little overlap between the five virus networks, which is also seen for other large 
interactome studies [143, 144]. In contrary, analysis of the predicted interactions indicates 
that there is a considerable amount of conserved interactions, which is not evident from the 
Y2H studies alone. Also, very few of the PPIs known from literature were detected in our 
Y2H studies, once again indicating that the studies have a high false negative rate. Based on 
the CoIP data it is possible to stipulate a false negative rate ranging from 59 - 78 %, when 
looking at the difference between predicted interactions confirmed by CoIP and those 
confirmed by Y2H. If we however use the previous published interactions as a reference, the 
false negative rate is 63 – 90 % for the intraviral studies (VZV and EBV was not included 
since no published interactions were detected). While these numbers have a high degree of 
uncertainty, they indicate that there are still a large number of intraviral PPIs which remain to 
be detected. From our virus-host study, only one published interaction was detected, 
indicating that the false negative rate in this screen was even higher than in the intraviral 
studies. 
 
 35
 
Another problem connected to interactions obtained from Y2H studies is that they are not 
separate in time and space. Some interactions might be limited to specific intracellular 
compartments, or to given time points. Especially for viral infections it would be of interest to 
know if a given interaction occurs right after the virus has infected a host cell, or later during 
the production of new infectious particles. By combining interactome data with microarray 
data, describing when certain genes are expressed, it is possible to obtain a better 
understanding of when specific interactions may occur in the cell. Supplemental tables S16 – 
S19 in Paper II summarizes the combination of KSHV-host interactions with expression 
profiles of the viral ORFs derived from microarray studies by Jenner and colleagues [186]. By 
separating the viral ORFs into three different expression classes, it was possible to examine if 
some cellular proteins were mainly targeted by viral ORFs within one specific expression 
class. Although this was the case for some genes (i.e. KRBA1, EMD and MRLP17), one can 
not entirely exclude that there is overlap in the expression profile of the three classes. Early 
genes and immediate early genes may be expressed throughout the viral cycle. In addition, 
structural proteins expressed late in infection will be part of newly formed infections particles, 
and their interactions may be associated with the initial takeover of a new host cell. More 
detailed studies are therefore necessary to draw more robust conclusions regarding when 
different interactions might take place during an infection.  
 
5.2 Biological relevance of experimental results 
Protein-protein interactions define literally all important aspects of the herpesviral biology, 
ranging form the initial attachment to the host cell, to assembly and release of newly formed 
virus particles. Here we present a massive number of newly discovered intraviral and virus-
host interactions. While it is impossible to go into detail on all of these novel interactions, the 
observed PPIs have revealed general aspects of intraviral interactions and of how virus 
proteins interact with cellular proteins.  
 
Paper I suggests that intraviral PPI networks are topologically different from cellular PPI 
networks. While cellular networks are scale-free, and display a high degree of local 
clustering, this is not the case for viral networks. As previously mentioned, having a scale-
free topology might be beneficial for the cell due to the tolerance towards random failure 
[169]. Whether there is any biological relevance in intraviral networks having a different 
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topology is however less certain. Intraviral PPI networks represent a combination of 
interactions that take place within the virusparticle and at different time points within the 
infected cell. Also, when considering that a virus is literally a lifeless particle without its host, 
the resulting intraviral network does not really reflect any actual model of an in-vivo 
situation. However, if these networks are combined with virus-host interactions, the resulting 
combined network may give a better representation of the network topology of an infected 
cell. Interestingly, in Paper I we observed that the intraviral network adapts to the topology of 
the cellular network when connected through predicted virus-host interactions. Further studies 
into the topology of combined pathogen-host networks may allow the differentiation of a 
healthy cell and an infected cell, based only on the properties of the interaction networks.  
 
In Paper II we reported that viral proteins tend to interact with cellular hubs, and that this 
holds true for both the KSHV-host and the VZV-host analysis. This finding was also recently 
reported in another virus-host Y2H study, between EBV ORFs and cellular proteins [185]. 
Since the same conclusion has been drawn for three separate herpesviruses, in two different 
studies, it is plausible that the targeting of hubs is a common phenomenon in herpesvirus-host 
interactomes. From a topological point-of-view, scale-free networks (like cellular networks) 
are tolerant to random failure, but highly susceptible to targeted attacks directed at hubs [169]. 
Targeting hubs may thus be the virus’ strategy for maximizing their impact on the host 
network. Also from a more biological perspective it makes sense for the virus to target highly 
connected proteins. Since herpesviruses affect a large variety of cellular functions, like 
transcription, proteasome activity and cytoskeletal rearrangement [104, 187], it is more 
efficient for the virus to target central components for each of these functions. 
 
Paper III indicates that a substantial portion of interactions among core herpesviral proteins 
are conserved, despite generally low sequence similarity. From literature there are several 
examples of interactions between core proteins that are conserved among several herpesvirus 
species from different subfamilies; e.g. HSV-1 UL31 and UL34 [93, 94, 188], HSV-1 UL54 
self-interaction [189, 190], HSV-1 UL15 and UL28 [89, 191]. Indeed much of what is 
currently known about herpevirus biology is derived from studies done in Herpes Simplex, 
which are assumed to hold true for other species as well. Other studies has indicated that it is 
possible to transfer PPIs from one species onto another [173, 180], which seems to be in 
accordance with what we see for herpesviral interactions. There have also been attempts to 
study the level of sequence similarity needed to confidently transfer interactions from one 
 
 37
species onto another. Yu and colleagues observed that interactions could be confidently 
transferred from one species to another if the joint sequence similarity of the interacting 
orthologs were > 80% [192]. However, Paper III indicate that the transfer of interactions 
between herpesvirus species must be somewhat different since none of the core proteins 
studied share such a high degree of sequence similarity. Indeed, we observed no correlation 
between sequence similarity and the number of species in which an interaction was 
conserved. From our finding it is clear that a high degree of sequence similarity is a poor 
criteria when predicting interactions from one species onto another, at least in the case of 
viruses.  
 
When comparing the number of intraviral and virus-host interactions from both core and non-
core proteins, it was observed that core proteins tended to have more host interactions (Paper 
II). This was somewhat surprising since most of the herpesviral genes reported to be involved 
in virus-host interactions, e.g. immune-evasion or anti apoptotic functions, are indeed species 
specific proteins [193]. The result may on the other hand give an indication of why conserved 
proteins are conserved. Since the mutation rate is higher in herpesviruses than in mammals 
[194], a large number of host interactions might result in an evolutionary pressure against 
mutation in core proteins. 
 
5.3 Specific interactions of interest 
In the three studies presented here 1007 intraviral and 1128 virus-host interactions have been 
reported. From the intraviral interactions 47 was observed in more than one species, reflecting 
possible conservation across different species of herpesvirus. With such a large number of 
interactions observed it is impossible to examine all of them in detail, but we can however 
speculate on which function they might have during the viral replication cycle. In this section 
some of the more interesting interactions will be discussed in detail and in relation to what is 
know from literature. 
 
5.3.1 Function of M51 
 
mCMV M51, and its orthologs HSV-1 UL33, VZV ORF 25, EBV BFRF4 and KSHV ORF 
67.5, were observed to have a number of interesting interactions in the intraviral Y2H screens. 
From the overlay network presented in Paper III the interaction between M51 and M53 was 
observed in four different species, with HSV-1 being the only species where it was not 
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observed. Interestingly, from the retesting of UL33 interaction on rising concentrations of the 
auto-activation inhibitor 3-AT (Paper III, Supplementary Figure 13), the interaction between 
UL33-UL31 stands out as one of the positive interactions. These results were however not 
included in the HSV interactome, to prevent an overrepresentation of interactions tested more 
than once. M53 has been extensively documented to be involved in nuclear egress through its 
binding to M50 [94, 195-197]. M51 was observed to interact with M50 in one species (VZV), 
although also this interaction stands out as positive in the UL33 retesting. In addition to Y2H, 
immunofluorecense studies indicated that M51 co-localize with both M53 and M50 when 
using fluorescent fusion proteins. From these result one might speculate that M51 plays a role 
in nuclear egress, through interactions with M53 and/or M50. 
 
Previous studies have indicated that HSV-1 UL33, the ortholog of mCMV M51, is involved 
in packaging of DNA. HSV-1 strains with temperature sensitive mutations within the UL33 
gene was shown to be incapable of proper cleavage and packaging of concatomeric DNA into 
preformed capsids [88]. Other studies have suggested that UL33 is probably more involved in 
cleavage of DNA due to its ability to interact with subunits in the terminase complex (UL28 
and UL15) [90]. A recent report have suggested that UL33 is necessary to stabilize the 
complex of UL28 and UL15 [91]. In the Y2H studies presented here UL33 was observed to 
interact with UL15 in three different species (not including HSV-1), while the interaction 
between UL33 and UL28 was observed in 2 species (HSV-1 included). These results seem to 
correlate well with what has been previously published for HSV, also indicating that these 
interactions might be conserved throughout the herpesvirus subfamilies. It also exemplifies 
that by generating an overlap network from several genome-wide Y2H screens in related 
species, it is possible to address the high number of false negative interactions within each 
individual analysis.  
 
When combining the previously mentioned interaction between M51 and M53/M50 with 
published interactions between UL33 and UL28/UL15, one might speculate whether M51 is 
involved in both packaging and egress. From studies done in HSV it was shown that UL33 is 
associated with capsids during packaging of DNA and that this association is independent of 
UL28 and UL15 [198]. Later studies by the same group have indicated that UL33 is located 
on the external surface of capsids [199]. To my knowledge, no proteins has been identified to 
attach UL33 to the capsid. However, in the mCMV Y2H analysis M51 was observed to 
interact with the smallest capsid protein m48.2. Whether this holds true for HSV is less 
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certain, but it would fit the description of UL33 attaching to the surface of the capsid. From 
immunofluorecense studies it has been shown that HSV-1 UL33 is located within nuclear 
replication compartments of infected cells late in infection [200]. However, Yamauchi and 
colleagues showed that when HSV-2 UL33 was transiently transfected into cells it displayed a 
cytoplasmic staining pattern [201]. This is similar to what was observed for M51-YFP fusion 
proteins transfected into HeLa cells (Paper III). Yamauchi and colleagues could also show 
that co-transfection with UL14 resulted in a re-localization of UL33 into the nucleus. From 
our Y2H studies the orthologs of UL33 was observed to interact with UL14 in two species 
(mCMV and KSHV). Additional experiments, not included in Paper III, could show that 
M51-EGFP fusion proteins was translocated to the nucleus of HeLa cells when co-transfected 
with M95-DsRed2 (Figure 5.1). From the immunofluoresence studies, the Y2H analysis and 
the previous publications it seems likely that UL14 translocation of UL33 represent a 
conserved function in herpesviruses.  
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Figure 5.1: M95 translocates M51 into the nucleus of transiently transfected HeLa cells. A) 
While M51-GFP (M51 fused N-terminally to EGFP) transfected into HeLa cells gives a 
cytoplasmic staining patter, b) M95-DsRed2 gives a clear nuclear staining pattern. C) Co-
transfecting M51-GFP and M95-DsRed2 however leads to a relocalization of M51-GFP into 
the nucleus of the cell.  
 
5.3.2 Other interactions of interest 
 
DCTN1 (dynactin 1, p150 subunit) is the large subunit of the dynactin complex involved in 
retrograde transport along microtubule. Herpes Simplex virus capsids have been reported to 
use dynein and dynactin for efficient transport from the cell periphery to the nucleus [78]. 
Blocking dynactin activity inhibits this transport [202], and it is believed that viral protein(s) 
interacting with dynactin are located within the inner tegument layer [203]. KSHV has also 
been reported to use dynein motors for transport to along microtubule, although the specific 
viral or cellular proteins involved in the process remains to be identified [79]. From Paper II it 
was observed that both VZV and KSHV interacted with DCTN1. Indeed two separate viral 
proteins in each virus interacted with DCTN1, although these proteins were not othologous 
between the two viruses. When considering the published results for HSV-1 together with the 
interactions presented here, one might speculate that the use of dynein and dynactin represents 
a common strategy of herpesviruses for transporting capsids to the nucleus. 
 
IKBKAP (inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase complex-
associated protein) is a part of the NF-κB pathway, as an upstream regulator of NF-κB-
inducing kinase (NIK) and IκB kinases (IKK) [204]. NF-κB activation has been reported to 
play an important role in the pathogenesis of several herpesviruses, with several reports 
claiming it is essential for viral replication [205, 206]. However, viral proteins have also been 
reported to inhibit NF-κB activation as an immune evasive strategy [207]. Interestingly, 
KSHV ORF K10.5 (which we observed to interact with IKBKAP) has previously been 
reported to inhibit NF-κB activation through binding to IKKβ [208]. This binding was 
observed in vitro, but failed to be reproduced in KSHV infected-BCBL cells. One can 
speculate whether other cellular proteins are involved in stabilizing the interaction. While 
there are no viral proteins known to inhibit NF-κB activation in VZV, HSV-1 ICP27 has been 
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suggested as a candidate to modulate NF-κB activation in as a means of inhibiting cytokine 
expression [209].  
 
The KSHV protein ORF19 gave 35 interactions in the KSHV-host analysis, and its ortholog 
VZV ORF34 gave 7 interactions in the VZV-host analysis (VZV-all). When going into more 
detail on the different interaction partners of ORF19 it was observed that several of them have 
been reported to be involved in functions related to chromatin remodeling and transcriptional 
regulation. Interacting proteins such as MYST2 and HTATIP are both histone 
acetyltransferases [210, 211], whereas SETDB1 is a histone methyl transferase [212]. ORF19 
also interacted with CBX5 (Heterochromatin binding protein1 (HP1)) which is involved in 
transcriptional silencing [113], and ING5 which have been reported to involved in regulation 
of chromatin acetylation and gene expression [213]. In addition ORF19 interacted with 
MCM3AP which is an acetyl tranferase involved in DNA replication [214] and SP110 
(nuclear body protein) which may act as activator of gene transcription [215]. From these 
interactions one might speculate that ORF19 is involved in transcriptional regulation of viral 
and/or cellular genes. From the VZV-host analysis, VZV ORF34 was observed to interact 
with two different variants of histone H2A, also suggesting a possible connection to DNA and 
chromatin. However, from literature UL25 was initially reported to be required for 
encapsidation of DNA into capsids in HSV-1 [216]. These results have however later been 
disputed in studies which indicate that low levels of HSV-1 DNA could still be packaged in 
UL25 mutant viruses [217]. A separate study from Ogasawara and colleagues has indicated 
that UL25 is able to bind DNA [218], and several studies has indicated that UL25 is 
associated with mature capsid particles [218-220]. The fact that UL25 is able to bind DNA 
could be interesting when combined with the cellular interactors involved in gene regulation 
and chromatin remodeling, and may open for further studies into the function of this protein.  
 
5.4 Future validation of interactions 
As previously mentioned the large number of interactions presented in these studies makes it 
difficult to validate or retest all of them. The general approaches of large scale interactome 
studies have been to retest a subset of interactions, and then to extrapolate from these results 
an estimate of the false positive rate. In the studies presented here co-immunoprecipitation has 
been used as a second method to evaluate the outcome of the Y2H analysis. This technique is 
however far too laborious for retesting all interactions observed. Further development of 
 
 42
reliable methods for retesting interactions in a more “intermediate-throughput” fashion is 
therefore needed. Such studies are indeed in progress with several promising novel methods 
for detecting protein-protein in mammalian cells, including LUMIER (luminescence-based 
mammalian interactome mapping) [221], FRET (Förster resonance energy transfer) [222] in 
addition to protein complementation assays like the β-lactamase assay [223]. While these 
techniques are promising they also have specific limitations, like the need for expensive 
equipment and difficulties in establishing the procedures. So the need for easy-to-use and 
moderately priced methods is still present.  
 
High content screening is another field which has been in rapid development over the last few 
years. By combining microscopy (live-cell, immunofluoresence and/or bright field) and high-
throughput automation it is possible to obtain large quantities of data, either from monitoring 
the growth and development of living cells exposed to different conditions, or through 
imaging of fixed cells. These types of studies produce a large quantity of images which can be 
processed by specific software to identify differences in cell morphology, viability or sub-
cellular localization of labeled proteins. This technology represents one possible method for 
doing different functional studies of herpesviral proteins on a genome-wide scale. For 
example studies of cellular localization, both of viral proteins and of cellular proteins, has 
already been published [224, 225], suggesting that similar studies may be performed on 
herpesviruses. There has also been a recent publication where high content screening has been 
used to study siRNA knock down of cellular proteins on a larger scale. Neumann and 
colleagues used siRNAs against 49 different cellular targets to study which proteins are were 
involved in chromosome segregation [226]. One can imagine that a similar approach could be 
used to study the effect of knocking down different cellular genes on the replication of a 
herpesvirus, thus giving an indication of which cellular genes are essential for the virus to 
efficiently replicate. These results could then be correlated with e.g. interactome data in an 
attempt to identify essential virus-host interactions.  
 
In addition to helping our understanding of the basic biology of herpesviruses, these large 
scale interactome studies can be beneficial from a clinical viewpoint. As indicated in the 
introduction, herpesviruses are connected to a variety of diseases in man. Any knowledge that 
could be used to improve drugs or disease treatment would therefore be helpful. One such 
possibility is extracting potential new targets for antiviral drugs from the protein-protein 
interactions. Especially the intraviral interactions that seem to be conserved throughout the 
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herpesviridae may be interesting targets for small-molecule inhibitor screens, where one 
chemical might have an inhibitory effect on several species of herpesviruses. This also holds 
true for the cellular targets. Any interaction with cellular genes that are essential for virus 
replication may prove valuable in the search for new forms of medication. There is however 
needs to further verify and study these interactions before moving on to the search for 
possible inhibitors. 
 
5.5 Concluding remarks 
Through the data presented here it is apparent that genome-wide interactome studies of both 
intraviral and virus-host interactions are not only feasible, but also provides a large amount of 
novel data. While single interactions of biological interest can be manually extracted from the 
data, further bio-informatical processing allows us to make observations and hypothesizes of 
a more general nature. However, since the fields of interactomics and system biology in 
general are quite new, there is a limited amount of publications available. This holds 
especially true for herpesviral interactomics where there are so far only two published papers 
available. One presented here (Paper I), in addition to the publications by Calderwood et al. 
[185] (which incidentally was published during the final preparations of Paper II and III). The 
lack of literature has made correlating our findings to previous publications difficult, and 
while on one hand we can claim that much of the data presented here is truly novel, further 
independent studies will need to confirm our findings. It is therefore comforting that one of 
the observations done for the virus-host networks, that viral proteins target hubs, was also 
observed in the EBV-host network from Calderwood et al.[185]. As more interactomes 
becomes available, for both viruses and other pathogens, it will become possible to further 
assess the validity of our other findings. 
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